HER2 Inhibitors Global Market Report 2023 – By Treatment (Monotherapy, Combination Therapy), By Application (Squamous Cell Carcinoma, Adenocarcinoma, Large Cell Carcinoma, Breast Cancer, Other Applications), By End User (Hospitals, Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2023-2032

HIV Drugs Market Definition

The post-harvest treatment refer to a variety of products that are treated before storage in order to reduce spoilage and improve appearance and marketability. Post-harvesting treatment mainly focuses on the treatment methods for fresh fruits and vegetables through crop treatments such as degrading, curing, wax coating, and application of growth regulators. These treatments are also effective in reducing cooling damage in refrigerated storage. The main types of post-harvest treatments are coating, ethylene blockers, fungicides, cleaners, sanitizers, and sprout inhibitors. Coatings are used in post-harvest treatments such as surface coating, heat treatments, irradiation, and ethylene to improve vitamin C retention during storage of citrus fruits. The coating of fruits will keep fruits fresh for longer periods of time. Post-harvest treatments are applied to fruits and vegetables. The global post harvest treatment market is segmented - 1) By Type: Coatings, Ethylene Blockers, Fungicides, Cleaners, Sanitizers, Sprout Inhibitors 2) By Application: Fruits, Vegetables The global post-harvest treatment market size grew from $1.45 billion in 2022 to $1.57 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The post-harvest treatment market size is expected to grow to $2.2 billion in 2027 at a CAGR of 8.7%. An increase in awareness of post-harvest treatments is expected to propel the growth of the post-harvest treatment market. Post-harvest treatment is applied in order to reduce spoilage and improve appearance and marketability. Post-harvesting treatment mainly focuses on the preparation methods for the fresh fruit market that are commonly used after crop treatments. This process starts when the crop is removed from the ground. The government is showing interest in these post-harvest techniques. The government has taken a number of steps in order to improve post-harvest treatment in various states of the country. For instance, under the mission for Integrated Development of Horticulture, the government is constructing cold storage for goods and has granted $25.2 billion to farmers for the years 2019–2020, as well as started educating farmers on post-harvest techniques. Therefore, increasing awareness of post-harvest treatment drives the post-harvest treatment market. Major players in the post-harvest treatment market are JBT Corporation, Syngenta, Nufarm, AgroFresh, Decco, Bayer, Pace International, Xeda International, Fomesa Fruitech, Citrosol, Post Harvest Solution Ltd., Januaryssen PMP, Futureco Bioscience, Apeel Sciences, Polynatural, Sufresca, Ceradis, and Agricoat natureseal LTD. Strategic collaboration between companies is a key trend gaining popularity in the post-harvest treatment market. Companies that are into post-harvest treatment are undergoing partnerships and collaborations to develop new technologies and products. For instance, in June 2020, AgroFresh Solutions, Inc., a US-based company and a leader in the post-harvest treatment industry, announced that it had entered into an agreement to sell $150 million to Paine Schwartz Partners. This investment will enable Paine Schwartz Partners to move initiatives in the field of post-harvest treatment forward more quickly. In June 2021, JBT, a US-based leading food safety technology company, acquired Prevenio for $170 million. Through this acquisition, Prevenio will be part of JBT Corporation and will operate under the JBT Corporation name. This acquisition will enhance the company’s recurring revenue portfolio while building on investments in solutions that support its customers in the post-harvesting industry. Prevenio is a company operating in post-harvesting based in New Jersey. Asia-Pacific was the largest region in the post-harvest treatment market in 2022 and is also expected to be the fastest-growing region in the forecast period. The regions covered in the post-harvest treatment market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the post-harvest treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The post-harvest treatment market consists of revenues earned by entities by providing pasteurization and freezing. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The post-harvest treatment research report is one of a series of new reports from The Business Research Company that provides post-harvest treatment statistics, including post-harvest treatment industry global market size, regional shares, competitors with post-harvest treatment shares, detailed post-harvest treatment segments, market trends and opportunities, and any further data you may need to thrive in the post-harvest treatment industry. This post-harvest treatment research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Antidepressants refer to a medication that aids in the treatment of depressive symptoms. Additionally, they can aid in the treatment of SAD, other anxiety disorders, and social anxiety disorder. Unpleasant side effects are possible with antidepressants. Initially, signs and symptoms including nausea, weight gain, or sleep issues can be prevalent. The main product types of antidepressants are selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressant (TCA), and monoamine oxidase inhibitor (MAOI). SSRIs (selective serotonin reuptake inhibitors) are a type of medication that is commonly used to treat depression and a few other mental illnesses. The various drug class includes monoamine oxidase inhibitors, serotonin antagonist and reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, and tricyclic antidepressants that are used for the treatment of the major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, and panic disorder. The global antidepressants market is segmented – 1) By Product: Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-norepinephrine Reuptake Inhibitor (SNRI), Tricyclic Antidepressant (TCA), Monoamine Oxidase Inhibitor (MAOI) 2) By Drug Class: Monoamine Oxidase Inhibitors, Serotonin Antagonist And Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Tricyclic Antidepressants 3) By Depressive Disorder: Major Depressive Disorder, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder, Panic Disorder The global antidepressants market size grew from $16.44 billion in 2022 to $17.41 billion in 2023 at a compound annual growth rate (CAGR) of 5.9% . The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global antidepressants is expected to grow from $25.52 billion in 2027 at a CAGR of 10.0% . The antidepressants market has also surged during the COVID-19 outbreak. The increasing number of cases and fatalities is affecting mental health by elevating anxiety worldwide. People who are already living with mental health problems are experiencing increased stress levels over the COVID-19 outbreak. This has triggered the demand for antidepressant drugs. Major players in the antidepressants market are Allergan PLC., AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC., H. Lundbeck AS, Johnson & Johnson, Pfizer Inc., Merck & Co. Inc., Sanofi, Sun Pharmaceuticals Pvt Ltd., Alkermes, Bristol Myers Squibb Company, Teva Pharmaceutical Industries, Eli Lilly and Co., Takeda Pharmaceutical Co. Ltd., Forest laboratories and Akeda Pharmaceutical . Globally, rising cases of mental health disorders are the key factor in the growth of the antidepressant drug industry, as many customers rely on these medications to counter depression, anxiety disorder, and other mental diseases. Antidepressant medications are used in conditions such as depression, OCD, childhood enuresis, major depressive disorder, severe anxiety disorder, bipolar disorder, post-traumatic stress disorder (PTSD), and social anxiety disorder. Globally, the percentage of people with depression varies from 2% to 6%, and the elderly are at greater risk of depression compared to other age groups. According to WHO, in 2020, about 264 million people of all ages worldwide suffered from depression. Therefore, rising cases of mental health disorders are expected to drive the growth of the antidepressant market. The side effects of antidepressant drugs are a key factor hampering the growth of the antidepressant market. For instance, the antidepressants Lexapro (escitalopram) and Celexa (citalopram), both are used to treat depression and Lexapro also helps for treating anxiety. Lexapro and Celexa can cause side effects common to others which include nausea, sleeplessness, sweating, dry mouth, and drowsiness. Celexa and Lexapro are both at risk for even more serious side effects including excessive bleeding, seizures, and vision issues. Therefore, the side effects of antidepressant drugs are expected to limit the growth of the antidepressant market. The treatment of resistant depression is a key trend in the antidepressant market. Ketamine is the new treatment that is used for anesthesia during surgery, stimulates the development of glutamate, and prompts the brain to form new neural connections. It makes the brain more adaptable and capable of developing new pathways and helps people to create more optimistic thoughts and behaviors. For instance, Food and Drug Administration (FDA) approved a new ketamine depression drug esketamine which is one-half of the ketamine compound. The drug must be administered as a nasal spray and patients must be taking another antidepressant at the same time. Also, the drugs can be prescribed to only those patients who have (unsuccessfully) tried two antidepressants before. In October 2021, ShineCo., Inc., a producer and distributor of Chinese herbal medicines, organic agricultural and hemp products, and other biotech products, announced that it has entered into a framework agreement to acquire a majority stake in Beijing Wonner Biotech Co., Ltd., for a deal amount of $30 million. Through this acquisition, Shineco aims to jointly develop SNG, a rapid-acting antidepressant natural innovative medicine. Beijing Winner is a biotechnology company based in China that specializes in the research and development of natural medicines and related products. North America was the largest region in the antidepressants market in 2022. Middle East is expected to be the largest growing region in the global antidepressants market during the forecast period. The regions covered in the global antidepressants market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the antidepressants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The antidepressants market consists of sales of duloxetine, desvenlafaxine, vilazodone, citalopram, and sertraline. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The antidepressants market research report is one of a series of new reports from The Business Research Company that provides antidepressants market statistics, including antidepressants industry global market size, regional shares, competitors with an antidepressants market share, detailed antidepressants market segments, market trends, and opportunities, and any further data you may need to thrive in the antidepressants industry. This antidepressants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Checkpoint inhibitors refer to an immunotherapy strategy that prevents immune checkpoint proteins from forming interactions with other proteins. Because of this, the T cells are able to destroy cancer cells because the "off" signal is not sent. One such medication works against the checkpoint protein CTLA-4. The main types of drugs in checkpoint inhibitors are PD-1 inhibitors, PD-L1 inhibitors, CTLA-4, chimeric antigen receptor T-cells, and others. PD-1 inhibitors and PD-L1 inhibitors are anticancer checkpoint inhibitors that impede the action of the immune checkpoint proteins PD-1 and PDL1 on the cell surface. It is used in lung cancer, renal cancer, blood cancer, bladder cancer, melanoma, and others, and is implemented in various sectors such as hospital pharmacies, retail pharmacies, and online pharmacies. The global checkpoint inhibitors market is segmented – 1) By Drug: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4, Chimeric Antigen Receptor T-Cells, Other Drugs 2) By Application: Lung Cancer, Renal Cancer, Blood Cancer, Bladder Cancer, Melanoma, Other Applications 3) By End-Users: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies The global checkpoint inhibitors market size grew from $23.93 billion in 2022 to $27.83 billion in 2023 at a compound annual growth rate (CAGR) of 16.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of the global checkpoint inhibitors market is expected to grow from $49.12 billion in 2027 at a CAGR of 15.3%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the checkpoint inhibitors market during the forecast period. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. Checkpoint inhibitors targeting the checkpoints are very helpful as cancer therapies. Therefore, the rise in cancer incidence rates globally is anticipated to boost for checkpoint inhibitors market demand. Major players in the checkpoint inhibitors market report are AstraZeneca PLC., Bristol-Myers Squibb Company, Merck & Co., Inc., Roche Holding AG, Pfizer, Incyte Corporation, Novartis AG, and NewLink Genetics Corporation. The high cost of checkpoint inhibitor cancer treatment is expected to limit the checkpoint inhibitor market. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for cancer has influenced the health conditions of the population and has led to a low-average life expectancy. For instance, the cost of a course of intravenous checkpoint inhibitor therapy is around $150,000 to $250,000, which is very expensive, especially for countries without public insurance. Therefore, the high cost of checkpoint inhibitor cancer treatment is expected to limit the checkpoint inhibitor market. Major companies in the checkpoint inhibitor market are forming partnerships or collaborations for the development of advanced technologies such as bifunctional fusion proteins or Y-trap. Most patients with cancer do not respond to immune checkpoint inhibitors. To make immunotherapies more effective, a group of researchers has developed the bifunctional fusion protein or Y-trap. This drug is created by fusing a receptor for a protein called TGF-beta that targets checkpoint proteins such as PD-L1 or CTLA-4. Y- Trap targets both a checkpoint inhibitor and TGF-beta and gives a more effective way to block the immune suppression and destroys the cancer cells. Merck, a prominent science and technology group, and GSK, a research-based global healthcare company, have announced that they have entered into a global strategic partnership to jointly create and market M7824 (bintrafusp alfa). M7824 is an investigational bi-functional fusion protein immunotherapy that is currently in clinical research, including possible registration trials, for various difficult-to-treat cancers. This includes a Phase II study to investigate M7824 compared to pembrolizumab as a first-line treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC). In another instance, in June 2020, Targovax, a Norway-based biotechnology company that develops immune activators for targeting solid tumors, entered into a collaboration with Leidos’ Explorations in Global Health (ExGloH) division for evaluating the potential of using ONCOS, a Targovax's clinical programme of oncolytic adenoviruses, as a vector to encode Microtide™ checkpoint inhibitor peptides. In June 2020, Targovax, a Norway-based biotechnology company, entered into a collaboration with the Explorations in Global Health (ExGloH) division of Leidos to evaluate the potential of using ONCOS, a Targovax's clinical programme of oncolytic adenoviruses, as a vector to encode microtide checkpoint inhibitor peptides. The Explorations in Global Health (ExGloH) division of Leidos has created a specific, proprietary portfolio of microbially-derived peptides called MicrotideTM that act as immune checkpoint inhibitors. Leidos is a US-based company that deals with defense, aviation, information technology, and biomedical research. North America is the largest region in the checkpoint inhibitors market in 2022. The Middle East is expected to be the fastest growing region in the global checkpoint inhibitors market share during the forecast period. The regions covered in the checkpoint inhibitors market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the checkpoint inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The checkpoint inhibitors market consists of sales of atezolizumab, avelumab, and durvalumab. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The checkpoint inhibitors market research report is one of a series of new reports from The Business Research Company that provides checkpoint inhibitors market statistics, including checkpoint inhibitors industry global market size, regional shares, competitors with a checkpoint inhibitors market share, detailed checkpoint inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the checkpoint inhibitors industry. This checkpoint inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Protein inhibitors refer to compounds that interfere with the steps directly involved in the production of new proteins in cells. Protein inhibitors operate at the ribosome level, benefiting from the significant variations between prokaryotic and eukaryotic ribosome architectures. The main product types of protein inhibitors are protein kinase inhibitors, monoclonal antibodies, and others. Monoclonal antibodies are laboratory-created molecules designed to act as substitute antibodies, restoring, enhancing, modifying, or mimicking the immune system's attack on unwanted cells, such as cancer cells. The protein inhibitors are used in the treatment of oncology, inflammatory diseases, and others, and are distributed by hospital pharmacies, independent pharmacies, and online pharmacies. The global protein inhibitors market is segmented - 1)By Product: Protein Kinase Inhibitors, Monoclonal Antibody, Other Products 2) By Application: Oncology, Inflamatory Diseases, Other Applications 3) By Distribution Channel: Hospital Pharmacies, Independent Pharmacies, Online Pharmacies The global protein inhibitors market size grew from $68.17 billion in 2022 to $74.3 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the protein inhibitors is expected to grow from $105.43 billion in 2027 at a CAGR of 9.1%. The increasing prevalence of chronic diseases is predicted to contribute to the growth of the protein inhibitors market over the forecast period. Chronic diseases such as cancer, cardiovascular diseases, and autoimmune diseases are becoming more prevalent. For instance, in May 2022, according to the World Health Organization, chronic diseases are expected to become the seventh leading cause of death globally by the end of 2030.In the USA, the number reached 157 million in 2020, with 87 million people having multiple conditions. Protein inhibitors are used for the treatment of these diseases attributing to fewer adverse effects and higher efficacy. Therefore, an increasing number of people with chronic diseases are anticipated to propel the demand for growth of the protein inhibitors market. Major players in the protein inhibitors market are Bayer AG, Astra Zeneca, Roche, Teva, Apotex, Novartis, GlaxoSmithKline, Pfizer, Boehringer Ingelheim, and F. Hoffmann-La Roche. The high cost of protein inhibitors used for cancer is anticipated to limit the growth of the protein inhibitors market shortly. Monoclonal antibodies are a type of protein made in the laboratory to bind substances in the body including cancer cells and are used to treat various types of cancer. Monoclonal antibody therapies are considered to be costlier when used for cancer. For instance, according to the National Center for Biotechnology Information, the average price of monoclonal antibodies was $96,731 for 34 monoclonal antibody indication combinations. Oncology and hematology monoclonal antibodies represented 40% of approved monoclonal antibody indication combinations, yet accounted for more than 85% of those priced at $100,000 or higher. The price of oncology or hematology monoclonal antibodies was $149,622 higher than those used in metabolic or cardiovascular disorders, $106,830 higher than in ophthalmology, $128,856 higher than in infectious diseases or allergies, and $98,981 higher than in immunology. Thus, the high cost of protein inhibitors including monoclonal antibodies for the treatment of cancer is expected to hinder the market’s growth. Companies in the protein inhibitors market are increasingly investing in various strategic initiatives such as partnerships and collaborations to develop new drugs to meet the market demand. Strategic collaborations and partnership agreements help companies to expand their existing product portfolio and geographical presence. For instance, in February 2020, Catalent, Inc., a USA-based provider of delivery technologies, drug manufacturing, gene therapies, biologics, and consumer healthcare products announced a partnership agreement with Zumutor Biologics Inc., an immune-oncology company based in the USA to manufacture ZM008, a monoclonal antibody targeting solid tumors. Moreover, in February 2021, Eli Lilly and Company, a USA-based pharmaceutical company, and Rigel Pharmaceuticals, Inc., a USA-based biotechnology company, announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications, including autoimmune and inflammatory diseases. In June 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, acquired ReViral for $525 million. The acquisition strengthens Pfizer's commitment to creating both medications and vaccines to help fight the respiratory syncytial virus while also expanding its anti-infective portfolio (RSV). ReViral is a UK-based clinical-stage biopharmaceutical company pioneering in the discovery and development of innovative antiviral drugs for disorders brought on by the respiratory syncytial virus. North America was the largest region in the protein inhibitors market in 2022. The regions covered in the global protein inhibitors market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the global protein inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The protein inhibitors market consists of sales of erythromycin, tetracycline, chloramphenicol, and aminoglycosides. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The protein inhibitors market research report is one of a series of new reports from The Business Research Company that provides protein inhibitors market statistics, including protein inhibitors industry global market size, regional shares, competitors with a protein inhibitors market share, detailed protein inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the protein inhibitors industry. This protein inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Immunosuppressant refers to a medication that prevents the immune system from attacking healthy cells and tissues. These medications are used to stop transplant rejection in recipients of stem cell and organ transplants. The medications also address the symptoms of autoimmune diseases. Immunosuppressants market are potent medications that need to be carefully monitored to prevent side effects. The main classes of drugs in the immunosuppressants market are corticosteroids, monoclonal antibodies (MABs), calcineurin inhibitors, mTOR inhibitors, anti-proliferative agents, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different indications include organ transplantation, autoimmune disorders, and non-autoimmune inflammatory diseases and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies. The global immunosuppressants market is segmented - 1) By Drug Class: Corticosteroids, Monoclonal Antibodies (mAbs), Calcineurin Inhibitors, mTOR Inhibitors, Anti-Proliferative Agents, Other Drug Classes 2) By Indication: Organ Transplantation, Autoimmune Disorders, Non-Autoimmune Inflammatory Diseases 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies The global immunosuppressants market size grew from $19.52 billion in 2022 to $22.59 billion in 2023 at a compound annual growth rate (CAGR) of 15.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global immunosuppressants is expected to grow from $38.35 billion in 2027 at a CAGR of 14.1%. The surge in organ transplant procedures such as kidney and liver transplants due to the rise in incidences of organ failure is the major factor driving the immunosuppressant market's growth. For instance, in June 2020, according to the United Network for Organ Sharing (UNOS), a US-based scientific and educational organization, 39,718 organ transplants were performed in the United States. Furthermore, according to the American Kidney Fund, a US-based health organization, on the national transplant waiting list in June 2022, there will be more than 106,000 people, of whom 92,000 (or 87%) are waiting for a kidney transplant in the US. The increasing number of cases of organ transplants and incidences of organ failure in patients is therefore expected to drive immunosuppressants market growth. Major players in the immunosuppressants market are Astellas Pharma, GlaxoSmithKline, Bristol Myers Squibb, Johnson & Johnson, Intas Pharmaceuticals Ltd., Mylan Laboratories Inc., Pfizer, Novartis, Novartis AG, and Sanofi S.A. Stringent government regulations are expected to hamper the growth of the immunosuppressants market. Through a stringent regulatory drug approval process, regulators such as the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) ensure public safety for food and drugs. For an immunosuppressant drug to be approved by the regulatory authorities, the sponsor must provide satisfactory evidence regarding the safety and efficacy of a drug in a patient with a defined clinical condition. Sponsors should submit to the Center for Drug Evaluation and Research (CDER) any information on the immunotoxicology evaluation of drugs whenever such information becomes available, for review. Many guidelines have also been adopted by the EU, including those providing general guidance, more specific guidance on quality issues, and non-clinical and clinical aspects. Therefore, the stringent regulatory and approval process for immunosuppressant drugs is projected to hamper the overall growth of the immunosuppressants market. Phenotypic personalized medicine or PPM or a hybrid of artificial intelligence and physician intervention is a new approach to overcoming the issues with immunosuppressants. For instance, tacrolimus is the most widely used immunosuppressant for patients who are undergoing organ transplantation. When the patient is in the hospital, Tacrolimus immunosuppressant levels must be checked regularly and changed frequently. A PPM approach that is based on a computational platform is used to overcome this concern. The inputs from the computational platform-based PPM approach include the past response of the patient to the dose of the drug and other drugs that are being taken, as well as current data on the liver and kidney. Using PPM, the physician can identify the optimal drug and dose combination from various possibilities. Therefore, it is believed that artificial intelligence is leading the way to not only more personalized and effective drug dosing but also enhancing physicians’ decision-making capabilities by providing clinical data rather than predicted responses. In October 2022, Amgen Inc., a US-based biopharmaceutical and biotechnology company, acquired ChemoCentryx Inc. for $3.7 billion. Through this acquisition, Amgen increases its inflammation and nephrology drug product portfolio and has three therapeutic candidates in the early stages that target chemoattractant receptors, additional inflammatory conditions, and an oral cancer checkpoint. ChemoCentryx, Inc. is a US-based biopharmaceutical company pioneering in the development and commercialization of novel drugs for cancer, autoimmune, and inflammatory illnesses. North America was the largest region in the immunosuppressants market in 2022. The regions covered in the immunosuppressants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the immunosuppressant market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The immunosuppressants market consists of sales of induction drugs, maintenance drugs, corticosteroids, and calcineurin inhibitors. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The immunosuppressants market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resale, either further along the supply chain or as part of other products. The immunosuppressants market research report is one of a series of new reports from The Business Research Company that provides immunosuppressants market statistics, including the immunosuppressants industry's global market size, regional shares, competitors with an immunosuppressants market share, detailed immunosuppressants market segments, market trends and opportunities, and any further data you may need to thrive in the immunosuppressants industry. This immunosuppressants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

TNF alpha inhibitors refer to medications that are used to treat inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis, and juvenile idiopathic arthritis and that help to reduce or eliminate inflammation. TNF inhibitors may increase the risk of skin cancer, particularly non-melanoma skin cancers like squamous cell carcinoma. The main types of drugs in TNF alpha inhibitors market are remicade (infliximab), enbrel (etanercept), humira (adalimumab), cimzia (certolizumab pegol), and simponi (golimumab). Remicade is a prescription medication for people with moderately to severely active Crohn's disease who haven't responded to other treatments.The different routes of administration include oral, subcutaneous, intravenous, and others and involve various types of diseases such as inflammatory bowel disease, psoriatic arthritis, ulcerative colitis (UC), rheumatoid arthritis, ankylosing spondylitis, and others. The global TNF alpha inhibitors market is segmented - 1) By Drug: Remicade (Infliximab), Enbrel (Etanercept), Humira (Adalimumab), Cimzia (Certolizumab Pegol), Simponi (Golimumab) 2) By Route Of Administration: Oral, Subcutaneous, Intravenous, Other Route Of Administration 3) By Disease Type: Inflammatory Bowel Disease, Psoriatic Arthritis, Ulcerative Colitis (UC), Rheumatoid Arthritis, Ankylosing Spondylitis, Other Disease Types The global TNF alpha inhibitors market size grew from $40.73 billion in 2022 to $42.2 billion in 2023 at a compound annual growth rate (CAGR) of 3.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global TNF alpha inhibitors is expected to grow from $44.95 billion in 2027 at a CAGR of 1.6%. The growing prevalence of inflammatory diseases such as inflammatory bowel disease and psoriasis is a key factor driving the growth of the TNF alpha inhibitor market. Tumor necrosis factor-alpha (TNF alpha) inhibitors are commonly used in gastroenterology, dermatology, and rheumatology for the treatment of various immune-mediated inflammatory diseases. Globally, the prevalence of inflammatory bowel disease (IBD) is about 0.5-24.5 cases of ulcerative colitis per 100,000 person-years and 0.1-16 cases of Crohn's disease per 100,000 person-years, and overall, the IBD prevalence is 396 cases per 100,000 people each year. Thus, the increasing number of cases of inflammatory diseases increases the demand for TNF alpha inhibitors, contributing to the growth of the TNF alpha inhibitors market. Major players in the TNF alpha inhibitors market are AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., UCB S.A., Novartis International AG, Pfizer Inc., Merck & Co. Inc., Janssen Biotech, Ablynx, and Momenta Pharmaceuticals. The adverse side effects of TNF alpha inhibitors on patients are expected to limit the growth of the TNF alpha inhibitor market. The multiple adverse effects of TNF alpha inhibition identified by clinical trials and post-marketing surveillance include injection site reactions, neutropenia, infusion reactions, and infections. According to the U.S. According to the Food and Drug Administration (FDA), TNA alpha inhibitors can cause serious infections in people with weaker immune systems or low resistance levels. The infections can be bacterial, mycobacterial, fungal, or viral, leading to various diseases such as tuberculosis, histoplasmosis, candidiasis, blastomycosis, and hepatitis B. These side effects force patients to prefer alternatives such as non-TNF biologics, which hampers the growth of the TNF alpha inhibitors market. The companies in the market are focusing on research and development for TNF alpha inhibitors market. The focus on research and development activities allows companies in the market to evaluate and accept high-quality research proposals from all over the world and provide biologically and clinically superior performance with a more comfortable patient experience and faster recovery times. For example, in February 2022, MyMD Pharmaceuticals, Inc., a US based clinical stage pharmaceutical company committed to extending healthy lifespan, announced Phase 1 clinical trial data demonstrating MYMD-1’s reduction of tumor necrosis factor-alpha (TNF-a), the molecules that are the root cause of aging, in the blood of healthy human subjects. MYMD-1 has shown effectiveness in pre-clinical studies in regulating the immune system by performing as a selective inhibitor of tumor necrosis factor-alpha (TNF-a), a driver of chronic inflammation. AbbVie Inc., a biopharmaceutical company based in the United States, completed the $63 billion acquisition of Allergan plc in May 2020.The acquisition is expected to expand and diversify AbbVie Inc.’s revenue base and its existing immunology portfolio. Allergan plc is an Ireland-based pharmaceutical company engaged in manufacturing and marketing drugs and medical devices in the areas of the central nervous system, eye care, medical aesthetics, and gastroenterology. North America was the largest region in the TNF alpha inhibitors market in 2022. The regions covered in the TNF alpha inhibitors analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the TNF alpha inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The TNF alpha inhibitors market consists of sales of infliximab, adalimumab, etanercept, golimumab, and certolizumab. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The TNF alpha inhibitors market research report is one of a series of new reports from The Business Research Company that provides TNF alpha inhibitors market statistics, including global market size, regional shares, competitors with a TNF alpha inhibitors market share, detailed TNF alpha inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the TNF alpha inhibitors industry. This TNF alpha inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Interleukin inhibitors refer to a substance used to suppress the immune system that prevents interleukins from working. Interleukins are a class of cytokines produced by white blood cells in response to infection (lymphocytes, monocytes, and macrophages). They are crucial to the control of the immune system. The main types of interleukin inhibitors are IL-17, IL-23, IL-1, IL-5, IL-6, and others. Interleukin 17 is a pro-inflammatory cystine knot cytokine family. In response to IL-23 stimulation, they are produced by a subset of T helper cells known as T helper 17 cells. The different applications include psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease, and others, and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies. The global interleukin inhibitors market is segmented - 1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6, Other Types 2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, Other Applications 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies The global interleukin inhibitors market size grew from $31.73 billion in 2022 to $36.96 billion in 2023 at a compound annual growth rate (CAGR) of 16.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global interleukin inhibitors is expected to grow from $68.56 billion in 2027 at a CAGR of 16.7%. An increase in the number of investigational drugs for inflammatory diseases such as psoriasis, arthritis, and inflammatory bowel disease will drive the interleukin inhibitors market. Inhibitors of interleukin decrease the actions of the inflammatory cytokines, stimulate innate immune responses to prevent damage to the host, and maintain normal tissue homeostasis. There are 48 molecules under investigation for the treatment of inflammatory diseases such as psoriasis and psoriatic arthritis. Among these, 20 molecules are in Phase III clinical trials. These growing numbers of pipeline drugs will drive the interleukin inhibitors market upon approval. Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical, and Regeneron Pharmaceuticals. High costs associated with biological therapy are hampering the interleukin inhibitors market. The biologic treatment that has revolutionized the care of psoriasis patients is more expensive than the other treatments. The total annual cost ranged from $2,077 to $13,132 in the US for psoriasis and from $10,924 to $17,050 for psoriatic arthritis, per patient. As of 2020, biologics treatment costs were around $10,000 to $30,000 per year. The higher price of biologics and low healthcare expenditure in developing countries are therefore likely to hinder interleukin inhibitors market growth. The patent expiration of biologic drugs creates opportunities for biosimilar drugs, which are a less expensive alternative. Major companies in the interleukin sector are focusing on developing biosimilars for interleukin inhibitors. For instance, biosimilars for IL inhibitors such as canakinumab (Ilaris), ustekinumab (Stelara), tocilizumab (Actemra), and secukinumab (Cosentyx), among others, are in development by Mabpharm, NeuClone Pharmaceuticals Ltd., Gedeon Richter, and Bio-Thera Solutions, respectively. Despite the clinical benefits associated with the use of biologics in psoriasis and other autoimmune diseases, many patients are not treated with biological therapy, and access to treatment may be limited for several reasons, including higher treatment costs. This factor, coupled with rapid advances in biotechnology and analytical sciences that ensure comparability of biosimilars to biological drugs, drives the trend for biosimilars. North America was the largest region in the interleukin inhibitors market in 2022. The regions covered in the interleukin inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the interleukin inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The interleukin inhibitors market consists of sales of anakinra, canakinumab, and rilonacept. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The interleukin inhibitors market research report is one of a series of new reports from The Business Research Company that provides interleukin inhibitors market statistics, including interleukin inhibitors industry global market size, regional shares, competitors with an interleukin inhibitors market share, detailed interleukin inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the interleukin inhibitors industry. This interleukin inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.